Histoblast Tablet contains Bilastine 20 mg, a second-generation antihistamine indicated for the relief of symptoms associated with allergic rhinitis and chronic idiopathic urticaria. Bilastine acts as a selective peripheral H1 receptor antagonist, effectively inhibiting the action of histamine, thereby reducing nasal and ocular symptoms such as sneezing, rhinorrhea, nasal congestion, itching, and watery eyes. Its high specificity for peripheral H1 receptors minimizes central nervous system penetration, resulting in a low incidence of sedation and other central side effects commonly associated with first-generation antihistamines. Histoblast is administered orally, with a recommended dosage of 20 mg once daily, preferably on an empty stomach to optimize absorption. Clinical studies have demonstrated its efficacy in improving quality of life in patients suffering from seasonal and perennial allergic rhinitis, as well as providing symptomatic relief in chronic urticaria characterized by pruritus and wheals. Bilastine has a favorable safety profile, with adverse effects generally mild and transient, including headache, dizziness, and gastrointestinal discomfort. It is contraindicated in patients with hypersensitivity to bilastine or any excipients. Caution is advised when co-administered with P-glycoprotein inhibitors. Histoblast Tablet offers an effective and well-tolerated option for managing allergic conditions requiring long-term antihistamine therapy.